# Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

> **NCT02437370** · PHASE1 · COMPLETED · sponsor: **University of California, Davis** · enrollment: 32 (actual)

## Conditions studied

- Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter
- Recurrent Bladder Carcinoma
- Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter
- Regional Urothelial Carcinoma of the Renal Pelvis and Ureter
- Stage III Bladder Urothelial Carcinoma
- Stage III Urethral Cancer
- Stage IV Bladder Urothelial Carcinoma
- Stage IV Urethral Cancer
- Urethral Urothelial Carcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Docetaxel
- **DRUG:** Gemcitabine Hydrochloride

## Key facts

- **NCT ID:** NCT02437370
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-01
- **Primary completion:** 2019-08-07
- **Final completion:** 2020-03-10
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02437370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02437370, "Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02437370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*